Truist analyst Richard Newitter raised the firm’s price target on Zimmer Biomet to $137 from $135 and keeps a Hold rating on the shares. The company delivered a "solid" Q4, and investor focus should now turn to out-year earnings growth potential, the analyst tells investors in a research note. The firm adds that it has increasing confidence in Zimmer Biomet’s top-line story given improving hip/knee market trends and the numerous positive mix opportunities that should help revenue growth to accelerate in 2023 and beyond.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target raised to $145 from $133 at Baird
- Zimmer Biomet price target raised to $135 from $130 at Piper Sandler
- Zimmer Biomet sees FY23 adjusted EPS $6.95-$7.15, consensus $6.98
- Zimmer Biomet reports Q4 EPS $1.88, consensus $1.83
- Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results
